Hologic, Inc. (HOLX)

76,71 -0,48 (-0,62%) Alla chiusura: 04:00PM EDT

Hologic, Inc.

250 Campus Drive
Marlborough, MA 01752
United States
508 263 2900
https://www.hologic.com

Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 6.990

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Stephen P. MacMillan	Chairman, CEO & President	4,12M	4,73M	1964
Ms. Karleen M. Oberton	Chief Financial Officer	1,6M	490,44k	1971
Mr. Essex D. Mitchell	Chief Operating Officer	925,29k	N/D	1980
Mr. John M. Griffin	General Counsel	1,47M	948,95k	1961
Mr. Jan Verstreken	Group President of International	1,44M	N/D	1968
Mr. Paul Malenchini	Chief Information Officer	N/D	N/D	N/D
Ryan M. Simon	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Peter P. Dunne	Senior Vice President of Human Resources	N/D	N/D	1956
Ms. Monica Aguirre Berthelot	VP & Chief of Staff	N/D	N/D	N/D
Mr. Erik S. Anderson	Division President of Breast & Skeletal Health Solutions	N/D	N/D	1982

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Hologic, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.